Detalles de la búsqueda
1.
Regulation and Role of αE Integrin and Gut Homing Integrins in Migration and Retention of Intestinal Lymphocytes during Inflammatory Bowel Disease.
J Immunol
; 207(9): 2245-2254, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34561227
2.
Mass cytometry panel optimization through the designed distribution of signal interference.
Cytometry A
; 91(1): 39-47, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27632576
3.
Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Inflamm Bowel Dis
; 28(9): 1348-1356, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34849918
4.
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Clin Cancer Res
; 14(9): 2775-84, 2008 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18451245
5.
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease.
Front Pharmacol
; 10: 39, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30774593
6.
Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Br J Pharmacol
; 176(19): 3805-3818, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31270798
7.
Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating ß7 Receptor Occupancy in Patients With Ulcerative Colitis.
J Clin Pharmacol
; 58(3): 386-398, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29178491
8.
Correction to: Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease: Results from a Phase 1 Randomized Trial.
Inflamm Bowel Dis
; 28(10): e143, 2022 Oct 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35366308
9.
Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
Br J Pharmacol
; 174(8): 628-640, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28009435
10.
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Mol Cancer Ther
; 12(7): 1255-65, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23598530
11.
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.
Mol Cancer Ther
; 8(10): 2937-46, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19808977
Resultados
1 -
11
de 11
1
Próxima >
>>